PharmaMar has announced the start of a pivotal Phase III ATLANTIS study evaluating efficacy and safety of PM 1183 (lurbinectedin)...
Ironshore Pharmaceuticals & Development, Inc. a wholly owned subsidiary of Highland Therapeutics Inc. has announced that the FDA has approved...